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Summary
 
Macrophages are typically stimulated by components of microbial cell walls. Surprisingly, cell
wall–less mycoplasmas can also very efficiently stimulate macrophages. We showed recently
that mycoplasma-derived lipopeptides constitute the active principle. We have now isolated a
clone of 
 
Mycoplasma fermentans
 
 expressing mainly one macrophage-stimulating lipopeptide.
This lipopeptide was detergent-extracted and isolated by reversed-phase high-performance liq-
uid chromotography, using nitric oxide release from C3H/HeJ mouse macrophages as bioassay
for detection. In contrast to “conventional” bacterial lipoproteins, this lipopeptide had a free
NH
 
2
 
 terminus. Amino acid composition, sequence, and the molecular weight of 2,163.3 are
consistent with the following structure: S-(2,3-bisacyloxypropyl)cysteine-GNNDESNISFKEK
with one mole C16:0, and a further mole of a mixture of C18:0 and C18:1 fatty acid per li-
popeptide molecule. The sequence could not be found in either the protein identification re-
source nor the Swiss Prot data bank. We named this 2-kD lipopeptide, macrophage-activating
lipopeptide-2 (MALP-2). Synthetic dipalmitoyl MALP-2 and mycoplasma-derived MALP-2
were compared with the bioassay. Both lipopeptides showed an identical dose dependency
with a half-maximal response at 10
 
2
 
11
 
 M concentration. MALP-2 may be one of the most po-
tent natural macrophage stimulators besides endotoxin.
 
A
 
part from being a nuisance in cell culture, where my-
coplasmas cause a wide spectrum of direct or indirect
effects, in particular on immune cells (for review see refer-
ence 1, for more recent work see references 2–4), infection
with these cell wall–less microorganisms may be associated
with clinical symptoms stretching from nongonococcal
urethritis (5, 6) to rheumatoid arthritis (for review see ref-
erences 7 and 8, and most recent evidence in reference 9)
and AIDS (10, 11). Most, if not all, events underlying these
symptoms are inflammatory. It is likely that mycoplasma-
mediated release of proinflammatory cytokines from mac-
rophages is involved. The general importance in human
disease of cytokine-inducing bacterial compounds, which
were named bacterial modulins, and the specific involve-
ment of cytokines in the pathogenesis of HIV-induced dis-
ease was acknowledged in two recent reviews (12, 13). Of-
ten macrophage activation was at first not recognized as
such, but detected through indirect effects on B or T lym-
phocytes, as exemplified by the 
 
Escherichia coli
 
 murein lipo-
protein which was first described as a B cell mitogen (14),
or the mycoplasma-derived macrophage activator MDHM
which was originally discovered as an inducer of CTLs (2,
15), respectively.
Macrophages are typically stimulated by components of
the microbial cell wall such as peptidoglycan fragments (16,
17), LPS (18, 19), lipoteichoic acid (20), and bacterial lipo-
proteins (21). Surprisingly, cell wall–less mycoplasmas can
also very efficiently stimulate macrophages (22). With the
one notable exception of 
 
Mycoplasma arthritidis
 
, a strain which
produces a well-characterized protein with superantigen
properties (23), the biochemical nature of putative mac-
rophage activators from mycoplasmas is not entirely clear,
and it was a matter of controversy which mycoplasmal
components were responsible for this stimulation (24–28).
Three independent studies recently reported that fractions
containing or enriched in lipoproteins from 
 
Mycoplasma fer-
mentans
 
 (27), 
 
Mycoplasma arginini
 
 (26), or yet other myco-
plasma species (28) show macrophage stimulatory activity
(MSA)
 
1
 
. However, no amino acid sequences were given,
nor could it be excluded that other contaminating compo-
 
1
 
Abbreviations used in this paper:
 
 Fmoc, fluorenylmethoxycarbonyl; MALDI,
matrix-associated laser desorption/ionization time of flight; MALDI-MS,
MALDI mass spectroscopy; MALP-2, 2-kD macrophage-activating lipopep-
tide; MSA, macrophage stimulatory activity; NO, nitric oxide.
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nents might be the active ones. The situation is further
complicated by the fact that mycoplasmas express several li-
poproteins.
We were recently able to formally prove that a lipopep-
tide with an acylated S-(2,3-dihydroxypropyl)cysteine NH
 
2
 
terminus is the active principle in a preparation from 
 
M. fer-
mentans
 
, formerly called MDHM (for mycoplasma-derived
high molecular weight material; 29). It was derived from a
proteinase K–treated detergent extract and possibly resulted
from a mixture of lipoproteins. This material stimulates hu-
man monocytes as well as murine macrophages to release
TNF, IL-1, IL-6, prostaglandins (2, 30) and, in the case of
IFN-
 
g
 
–primed murine macrophages, also nitric oxide (24,
31). Furthermore, it downregulates class II MHC expres-
sion on macrophages, resulting in impaired antigen presen-
tation to T cells (32).
It remained unresolved why lipopeptides from myco-
plasmas showed MSA at concentrations that were much
lower than lipoproteins from other bacterial sources, e.g.,
from 
 
E. coli
 
 (14, 21) or borrelia and treponema (33), which
are typically used at concentrations of 
 
z
 
1 
 
m
 
g/ml for half-
maximal response, and 10–50 
 
m
 
g/ml for optimal stimula-
tion. In contrast, macrophages can be half maximally stim-
ulated by heat-killed mycoplasmas at a concentration of 10 ng
mycoplasma protein/ml (e.g., reference 32). This indicates
that even crude, unseparated mycoplasma preparations show
a specific activity which is higher by several orders of mag-
nitude than that of lipoproteins from, e.g., gram-negative
bacteria. We have now isolated a clone from 
 
M. fermentans
 
expressing mainly one macrophage-stimulating lipopeptide
that we purified. In contrast to conventional bacterial lipo-
proteins (see review in reference 34), this lipopeptide has a
free NH
 
2
 
 terminus that enabled us to determine the complete
amino acid sequence. We named this compound MALP-2
for 2-kD macrophage-activating lipopeptide. MALP-2 is
half maximally active at 0.02 ng/ml corresponding to 10
 
2
 
11
 
M concentration. MALP-2 is the natural lipopeptide with
the highest specific MSA so far described. It even surpasses
the synthetic lipopeptide analogue CGP-31 362 (17) in its
MSA potential by two orders of magnitude (35).
 
Materials and Methods
 
Growth of Mycoplasmas, Isolation of Clones.
 
The 
 
M. fermentans
 
strain D15-86, originally recovered from a contaminated HL60
culture, was grown at 37
 
8
 
C in a 7.5% CO
 
2
 
 atmosphere for 3 d in
GBF-3 medium consisting of bicarbonate-buffered MEM 
 
a
 
 me-
dium, 10% heat-inactivated newborn calf serum (Sigma, Deisen-
hofen, Germany), 0.5% (wt/vol) Bacto Tryptone with 5 mM
fructose, and 10 mg/L of adenosine, guanosine, cytidine, uridine,
2
 
9
 
-deoxyadenosine, 2
 
9
 
-deoxyguanosine, 2
 
9
 
-deoxycytidine, and
2
 
9
 
-deoxythymidine. For isolation of clones, mycoplasmas were
filtered through a 0.45-
 
m
 
m filter and plated on 0.7% soft agar in
this medium. Single colonies were picked with the aid of a pas-
teur pipette under a stereo microscope and propagated further in
liquid medium. Mycoplasma cultures were split 1:10 every other
day until harvest, and washed with pyrogen-free saline. Myco-
plasmas were kept frozen at 
 
2
 
20
 
8
 
C until use.
 
Nitric Oxide Release Assay.
 
MSA was determined with the ni-
 
tric oxide release assay as described (24). In brief, it is performed
with peritoneal exudate cells from C3H/HeJ endotoxin low-
responder mice (Bomholtgaard, Rye, Denmark) in 96-well microti-
ter plates. Cells are simultaneously stimulated with 
 
r
 
IFN-
 
g
 
 and a
serial dilution of macrophage-activating material. After a 48 h incu-
bation period, nitrate is reduced with nitrate reductase, and nitric ox-
ide (NO) determined as the sum of nitrite and nitrate using Griess re-
agent. One U of MSA/ml is defined as the dilution of macrophage
stimulator required to obtain half-maximal NO release (24).
 
Detergent Extraction of Macrophage-activating Material.
 
A frozen
mycoplasma suspension containing 83-mg protein (36) in 16 ml
was thawed in the presence of 1 mM PMSF and 0.6 mM 
 
N
 
-(
 
a
 
-
rhamnopyranosyloxyhydroxyphosphinyl)-
 
l
 
-leucyl-
 
l
 
-tryptophane
sodium salt to deactivate and inhibit serin- and metalloprotein-
ases, respectively. The suspension was left overnight at 4
 
8
 
C and
then extracted with 30 ml chloroform/methanol (2:1) to remove
the bulk of phospholipids. The extraction was repeated three times
with 20 ml organic solvent. The water phase, including insoluble
material, was freed of organic solvent by rotational evaporation,
and treated for 2 h at 37
 
8
 
C with 5,000 U benzonase (Merck,
Darmstadt, Germany) in a final volume of 20 ml 0.01 M Tris Cl,
pH 7.6, 1 mM MgSO
 
4
 
. After addition of 20 ml PBS, 40 ml 100 mM
 
n
 
-octyl 
 
b
 
-
 
d
 
-glucopyranoside (octyl glucoside) were added and li-
pophilic proteins were extracted by heating in a boiling water
bath for 7 min. Insoluble material was removed by centrifugation
and the supernatant solution containing the MSA was pressure di-
alyzed on a YM-10 filter (Amicon, Beverly, MA) diluting the in-
ner dialysate several times with water to remove the detergent, fi-
nally concentrating the inner dialysate to 7.5 ml. This material was
kept frozen until further use.
 
Isolation of MALP-2 by Reversed Phase HPLC.
 
1 ml 100 mM
octyl glucoside and 100 
 
m
 
l 1 M CaCl
 
2
 
 were added to the inner
dialysate which was concentrated by freeze drying. The freeze-
dried material was dissolved in 1 ml 0.1 M NH
 
4
 
 acetate buffer,
pH 6.9, applied to an SP 250/10 Nucleosil 300-7 C8 column
(Macherey & Nagel, Düren, Germany), and was eluted at 40
 
8
 
C
with a linear water/2-propanol gradient.
 
Determination of Total Phosphate.
 
Total inorganic phosphate was
determined after oxidative digestion as described (37).
 
Amino Acid Sequence Analysis.
 
Aliquots of 2.5–10 
 
m
 
l were di-
rectly taken from HPLC fractions and applied to biobrene-
coated, precycled glass fiber filters of a Procise sequencer (494A;
Applied Biosystems, Foster City, CA), and sequenced according to
the manufacturers standard gas-phase programs (38).
 
Amino Acid Composition Analysis.
 
Amino acid analysis was
carried out on an amino acid analyzer (420A/H, Applied Biosys-
tems) with automated gas-phase hydrolysis (6 N HCl, 160
 
8
 
C, 75
min) and on-line analysis of phenylthiocarbamoyl amino acids on
an 130 HPLC with 920 data system.
 
Matrix-assisted Laser Desorption/Ionization Time of Flight Mass
Spectroscopy.
 
MALDI-MS was performed on a Bruker REFLEX
 
Ô
 
(Bruker-Franzen Analytik GmbH, Bremen, Germany) instrument
equipped with a nitrogen laser (337 nm, 3 ns pulse). Spectra were
recorded at an acceleration voltage of 20 kV. The instrument was
internally calibrated with bovine insulin. The resolution was 1:500.
Octyl glucoside (8 mM final concentration) was added to aliquots
from the HPLC for optimal signals (39). Such samples were
mixed 1:1 (vol/vol) with 100 mM 
 
a
 
-cyano-4-hydroxycinnamic
acid in 60% aqueous acetonitrile containing 0.1% TFA and al-
lowed to dry on the stainless steel target.
 
Synthesis of Lipopeptides.
 
Resin, amino acids, and reagents
were purchased from Calbiochem-Novabiochem (Bad Soden, Ger-
many). Solvents were obtained from Fluka Chemie AG (Buchs, 
1953
 
Mühlradt et al.
Switzerland) and 
 
N
 
-fluorenylmethoxycarbonyl-S-2,3-bis(palmi-
toyloxy)-(2-RS)-propyl-(R)-cysteine (Fmoc-Dhc[Pam
 
2
 
]-OH) was
synthesized as previously described (40). The lipopeptide was built
up using the fluorenylmethoxycarbonyl (Fmoc) protocol for solid
phase synthesis on an automated synthesizer (model 433A; Ap-
plied Biosystems). A Wang-PHB-resin loaded with tert-butoxy-
carbonyl–protected Fmoc-lysine residue was used as the solid
support. Resin substitution was 0.60 mmol/g, and 0.1 mmol of
amino acid was used for each coupling. The following side chain
protecting groups were used: Asn (triphenylmethyl), Asp, Glu
(tert-butoxy), Ser (tert-butyl), and Lys (tert-butoxycarbonyl). De-
protection of the Fmoc–amino acid attached to the resin was ac-
complished using piperidine. The amino acids were coupled using
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluo-
roborate and hydroxybenzotriazole (HOBt). Fmoc-Dhc(Pam
 
2
 
)-
OH was coupled in double excess to the resin-bound 
 
N
 
 13-mer
peptide with diisopropylcarbodiimide/HOBt in dimethylforma-
mide/dichloromethane (1:2) for 12 h (41). The peptide and all
protecting groups were cleaved from the resin with TFA contain-
ing phenole (5%), thioanisole (5%), ethanedithiole (5%), and wa-
ter (7%). The synthesis was monitored by electrospray ionization
mass spectrometry on a triple–quadrupole instrument (API III
TAGA X; Perkin-Elmer Sciex, Thornhill, Ontario, Canada).
 
Results
 
Different M. fermentans Clones Vary in their Macrophage-
stimulatory Potential.
 
Our earlier attempts in isolating mac-
rophage activating material from 
 
M. fermentans
 
 were often
frustrated by batches of mycoplasmas with low stimulatory
potential. In the knowledge that (
 
a
 
) mycoplasmal macrophage
stimulator is derived from lipoproteins or peptides (29), and
of (
 
b
 
) the antigen variability and variation of expression of
lipoproteins from mycoplasmas (42), we agar cloned myco-
plasmas from their original source, a contaminated HL60
cell line, to isolate highly active clones. In total, 103 clones
were picked at random, grown in liquid medium, har-
vested, and finally extracted with hot octyl glucoside. Mac-
rophage stimulatory activity is extracted in this mild deter-
gent (24). As an assay, we chose nitric oxide production by
IFN-
 
g
 
 stimulated macrophages from LPS low responder
mice. This can be used for quantitative estimation of mac-
rophage-stimulatory activity and allows one to define a U/ml
as that dilution which gives half-maximal NO production
(24). A comparison of the activity of some of these clones
normalized per milligram mycoplasma protein is shown in
Figure 1. Macrophage-stimulatory activity of clones from M. fermen-
tans. Individual colonies grown on agar were picked and then cultured in
liquid medium. Mycoplasmas were harvested and MSA was extracted
with hot octyl glucoside and determined in the NO release assay with
IFN-g–treated peritoneal exudate cells from LPS low-responder mice.
MSA was calculated as U/mg mycoplasma protein.
Figure 2. Comparison of sil-
ver stain and MSA in gel slices
after SDS-PAGE of M. fermen-
tans PG 18 type strain and clone
II-29/1. Samples were run in
15% gels in the discontinuous
buffer system of Lämmli under
reducing conditions, applying
10  mg mycoplasma protein per
lane for silver staining. 70 mg
were subjected to electrophoresis
on a neighboring lane. This lane
was cut in 3-mm segments which
were extracted in 0.3 ml hot
octyl glucoside for subsequent
determination of MSA. 
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Fig. 1 and shows a variation of specific activity from 5,000
to 240,000 U/mg mycoplasma protein, i.e., by a factor of
 
z
 
50. Some clones were recloned and retained their good
stimulatory properties (see, e.g., clone II 29 in Fig. 1).
Since the variation of MSA upon recloning was higher
than can be accounted for by experimental error, we spec-
ulate that it may be due to clonal variation.
The sensitivity of the NO release assay allowed the de-
termination of the differences in the expression of macro-
phage stimulatory lipoproteins and peptides from individual
clones after SDS-PAGE separation by sectioning the gel and
extracting the gel slices. As an example, clone II-29/1 and the
type strain PG18 are compared in Fig. 2. Contrary to our
expectations that a particularly active clone would exhibit a
great number of stimulatory molecules with different mo-
lecular weights, clone II 29/1 (recloned from clone II 29)
and similar clones in the high specific activity range showed
a simple pattern with mainly one activity band at the front.
Clone II 29/1 was chosen to isolate the macrophage stimu-
latory material.
 
Isolation of the Macrophage-activating Lipopeptide from M. fer-
mentans Clone II 29/1.
 
In our earlier studies, we primarily
used proteinase K–digested macrophage stimulator, since this
treatment did not destroy the activity and facilitated isola-
tion (24). We now isolated the undegraded material by a
previously established procedure with a final purification step
of reversed phase HPLC (29). The extraction procedure
and the yield in MSA after each step are outlined in Table
1. The elution pattern of MSA from clone II 29/1 is shown
in Fig. 3. Fractions near the MSA were also tested for phos-
pholipids by measuring inorganic phosphate. MALDI-MS
was obtained from the fraction showing maximal MSA and
gave a major peak at 2164.3 [M 
 
1
 
 H]
 
1
 
 and a minor one at
2186.0 [M 
 
1
 
 Na]
 
1
 
 (Fig. 4). After mild alkali treatment,
these peaks were shifted to lower molecular weight by
 
z
 
504 mass units, indicating a loss of a C16 plus C18 fatty
acid (not shown). To distinguish this 2-kD lipopeptide
from other lipoproteins of mycoplasma origin, we named it
MALP-2.
 
Amino Acid Analysis and Sequence of MALP-2.
 
The mate-
rial showing maximal macrophage stimulatory activity was fur-
ther analyzed for amino acid content and sequenced. Amino
acid composition, sequence, and molecular weight deter-
mination are consistent with the following structure: (S-[2,3-
bisacyl(C16:0/C18:0;C18:1)oxypropyl]cysteine-GNNDES-
NISFKEK. No NH
 
2
 
-terminal amino acid was found, in
 
Table 1.
 
Isolation of Macrophage-stimulatory Lipopeptide from M. fermentans, Clone II-29/1
 
Fraction Volume Protein MSA
 
ml mg/ml mg total U 
 
3
 
 10
 
2
 
6
 
/ml U 
 
3
 
 10
 
2
 
6
 
 total
 
Mycoplasma suspension 16 5.2 83 1.3 21
Delipidated, nuclease-treated, octyl
glucoside–extracted water phase 82 0.16 13 0.32 26
Pressure dialysate/concentrate 8.2 0.41 3.4 3.8 31
HPLC peak fractions 18 ND – – 21
Figure 3. HPLC of octyl glucoside extracted MSA from M. fermentans.
MSA was extracted as in Table 1. 2.6 3 107 U were applied to a 10 3
250–mm RP8 reversed phase column and eluted with 2-propanol. (solid
line) MSA as determined in the NO release assay; (dotted line) inorganic
phosphate to monitor phospholipids. The bar below OG shows where
octyl glucoside elutes from the column.
Figure 4. MALDI spectrum of HPLC-purified MALP-2. The lipopep-
tide gave rise to a [M 1 H]1 ion at m/z 2164.3 and a [M 1 Na]1 ion at
m/z 2186.0. The signal at m/z 2867.8 is due to the [M 1 2H]21 signal of
the internal calibration standard bovine insulin.1955 Mühlradt et al.
keeping with the previously observed instability of S-(2,3-
dihydroxypropyl)cysteine upon hydrolysis. This sequence
is new and could not be found in either the protein identi-
fication resource nor the Swiss Prot data bank. Noteworthy
is the absence of an NH2-terminal fatty acid substituent
which is found in most bacterial lipoproteins, exemplified
first by the murein lipoprotein (43). The calculated molec-
ular weight for MALP-2 with a 1:1:1 ratio of peptide/C16:
0/C18:0 would be 2164.7, as opposed to 2162.6 for a 1:1:1
ratio of peptide/C16:0/C18:1. The molecular weight of
2163.3, as determined for MALP-2 by MALDI, is compatible
with a fatty acid composition of 1 mol C16:0 and a further
mole of a mixture of C18:0 and C18:1 per MALP-2 molecule.
Specific Activity of MALP-2 and Comparison with Synthetic
MALP-2. A dose response curve of the same HPLC-puri-
fied sample of MALP-2 that was used for amino acid analysis
and whose content of MALP-2 was therefore exactly known
is shown in Fig. 5. The dose response curve was determined
in the presence and absence of octyl glucoside (Fig. 5 A).
In the presence of this detergent, half-maximal response
was seen at 0.002 ng/ml corresponding to 10212 M, or at 10
times  higher concentrations without detergent, respec-
tively. Synthetic dipalmitoyl MALP-2 and HPLC-purified
mycoplasma-derived MALP-2 was compared in Fig. 5 B.
To ensure maximal activity, both preparations were predi-
luted in octyl glucoside. They showed practically identical
dose response curves.
Discussion
The data presented here show that MALP-2, the mac-
rophage-activating substance from the M. fermentans clone
II-29/1, is a small lipopeptide with two ester-bound, long
chain fatty acids and a free NH2 terminus. We have not yet
determined the exact position of the different fatty acids,
as the synthetic analogue with two ester-bound palmitic
acids showed the same biological activity as the natural
MALP-2, suggesting that the exact nature of the fatty acid
moiety may not be decisive for the MSA. In a previous pa-
per (29) we had shown that the NH2 terminus of a similarly
active, proteinase K–treated compound is S-(2,3-dihydrox-
ypropyl)cysteine first discovered in Braun’s murein lipo-
protein (43). As this earlier isolated, proteinase K–treated
material was obtained from uncloned mycoplasmas and was
possibly derived from more than one parent lipoprotein, it
represented a mixture of lipopeptides.
It has been amply documented, in particular with syn-
thetic analogues of the E. coli murein lipoprotein and pep-
tides derived from it, that such synthetic lipopeptides con-
stitute potent macrophage and B cell activators (21, 41, 44,
45). Moreover, synthetic conjugates consisting of lipopep-
tides with T helper cell and CTL epitopes from viral or
bacterial proteins are efficient low molecular weight vac-
cines with a built-in adjuvant principle (46–48) capable of
in vivo priming of virus-specific CTLs (49, 50). It is still
surprising that the mycoplasma-derived MALP-2 and its
synthetic analogue are half maximally active at concentra-
tions as low as 10211 M, i.e., at working concentrations in
the same order of magnitude as those of lymphokines. This
working concentration can still be lowered by a factor of
10 by taking care of optimal solubility through predilution
in detergent (Fig. 5 A).
A wealth of information about which particular moieties
of the lipopeptides are functionally important has been forth-
coming from syntheses and assays of various analogues.
Thus the presence of both ester-bound fatty acids is a pre-
requisite for biological activity, whereas the amide-bound
fatty acid was found to be dispensable (41, 45). In fact, a
free amino group at the NH2 terminus was earlier shown to
lead to very efficient stimulatory compounds (41).
Figure 5. Concentration dependency of MALP-2 in the NO release assay. (A) HPLC-purified MALP-2 from M. fermentans clone II-29/1 prediluted
in octyl glucoside (solid line) or PBS (dotted line). (B) HPLC-purified MALP-2 (solid line) and synthetic dipalmitoyl MALP-2 (dotted line), both prediluted
in octyl glucoside. The diamond on the y-axis shows NO release of control cells with IFN-g only. Data are the average of triplicate determinations 6
standard deviation.1956 Mycoplasma-derived Macrophage-activating Lipopeptide
Naturally occurring lipoproteins with a free amino group
have previously been detected only in Rhodopseudomonas
viridis (41). They may, however, be rather common in my-
coplasmas, since, at least in Mycoplasma pneumoniae, whose
genome has been completely sequenced, the N-acyltrans-
ferase gene was not detected (51). Thus, it can be expected
that other lipoproteins or peptides of mycoplasmal origin
will show similarly high MSA as MALP-2, as long as they
contain both ester-bound fatty acids and as long as they are
equally soluble. Solubility in aqueous media will, of course,
depend on the amino acid composition and sequence. The
importance of optimal solubility is also emphasized in Fig. 5
where MSA of MALP-2 in PBS was compared with that of
detergent-solubilized MALP-2. The M. fermentans PG18 type
strain did indeed show a second band of MSA with lower
electrophoretic mobility as well as stimulatory material with
the migratory properties of MALP-2 (Fig. 2). At this stage of
our investigations, it is still unclear whether MALP-2 stems
from such a higher molecular weight precursor or what de-
termines its expression or appearance. An answer to these
questions may arise from genetic experiments.
One important aspect of MALP-2 and other mycoplasmal
lipoproteins or peptides is their probable role as pathogeni-
city factors in septic arthritis. Many bacteria (staphylococci,
streptococci, salmonella, yersinia, mycobacteria, borrelia,
etc.) can cause septic arthritis. There is no doubt that my-
coplasmas are also arthritogenic in several animal species.
Whether this also applies to humans is still under debate, al-
though evidence for mycoplasmas in human arthritic joints
(9, 52) strongly supports this possibility. It is almost certain
that microorganisms cause macrophage activation in the af-
fected joints which, in the case of mycoplasmal arthritis, is
likely to be due to the macrophage stimulatory properties
of lipoproteins that may in fact undergo antigenic variation
during a prolonged infection (51). It is interesting in this
context that lipoproteins from borrelia causing Lyme dis-
ease are also potent macrophage activators (33).
A second aspect could be the increasing awareness of the
presence of highly active MSA in mycoplasma-contami-
nated cell cultures and in products from such cultures, e.g.,
mAbs. Although most researchers are very cautious about
LPS contaminations, the fact that .30% of cells deposited
in cell culture collections are mycoplasma positive indicates
that the effects of contamination with mycoplasmas and
their products are possibly underestimated.
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